

Rhonda L Bitting

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4910530/publications.pdf>

Version: 2024-02-01

38
papers

1,984
citations

471509

17
h-index

414414

32
g-index

38
all docs

38
docs citations

38
times ranked

3700
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers. <i>Molecular Cancer Research</i> , 2011, 9, 997-1007.	3.4	586
2	Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. <i>Annals of Oncology</i> , 2013, 24, 1802-1807.	1.2	288
3	Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. <i>Endocrine-Related Cancer</i> , 2013, 20, R83-R99.	3.1	272
4	Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018, 1869, 117-127.	7.4	106
5	The prognosis and treatment of acquired hemophilia: a systematic review and meta-analysis. <i>Blood Coagulation and Fibrinolysis</i> , 2009, 20, 517-523.	1.0	78
6	Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer. <i>European Journal of Cancer</i> , 2017, 81, 228-236.	2.8	76
7	Flupirtine blocks apoptosis in batten patient lymphoblasts and in human postmitotic CLN3- and CLN2-deficient neurons. <i>Annals of Neurology</i> , 2002, 51, 448-466.	5.3	68
8	The role of epithelial plasticity in prostate cancer dissemination and treatment resistance. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 441-468.	5.9	59
9	Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 1346-1357.	7.0	58
10	A Phase II Trial of Temezirolimus in Men With Castration-Resistant Metastatic Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 397-406.	1.9	52
11	Syntaxin 6-mediated exosome secretion regulates enzalutamide resistance in prostate cancer. <i>Molecular Carcinogenesis</i> , 2020, 59, 62-72.	2.7	41
12	Development of a method to isolate circulating tumor cells using mesenchymal-based capture. <i>Methods</i> , 2013, 64, 129-136.	3.8	37
13	Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center. <i>Theranostics</i> , 2017, 7, 2914-2923.	10.0	31
14	Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. <i>Journal of Hematology and Oncology</i> , 2017, 10, 100.	17.0	28
15	A Phase Ib Study of Combined VEGFR and mTOR Inhibition With Vatalanib and Everolimus in Patients With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 241-250.	1.9	25
16	A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer. <i>Cancer</i> , 2021, 127, 2954-2965.	4.1	21
17	Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 301-309.	3.9	19
18	Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial. <i>European Urology Oncology</i> , 2021, 4, 948-954.	5.4	18

#	ARTICLE	IF	CITATIONS
19	Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 110.e1-110.e9.	1.6	17
20	Rapid Measurement of Total Body Water to Facilitate Clinical Decision Making in Hospitalized Elderly Patients. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2009, 64A, 664-669.	3.6	14
21	Potential Predictive Biomarkers for Individualizing Treatment for Men With Castration-Resistant Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 25-33.	2.0	13
22	Clinical Characteristics of Patients With Renal Cell Carcinoma and Metastasis to the Thyroid Gland. <i>Clinical Medicine Insights: Oncology</i> , 2017, 11, 117955491774398.	1.3	13
23	Racial Disparity in Response to Prostate Cancer Systemic Therapies. <i>Current Oncology Reports</i> , 2020, 22, 96.	4.0	11
24	High-dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma: Prognostic features and outcomes. <i>Leukemia and Lymphoma</i> , 2007, 48, 1728-1735.	1.3	10
25	Pazopanib and Statin-Induced Rhabdomyolysis. <i>Case Reports in Oncology</i> , 2018, 10, 954-957.	0.7	8
26	Trajectories in muscular strength and physical function among men with and without prostate cancer in the health aging and body composition study. <i>PLoS ONE</i> , 2020, 15, e0228773.	2.5	8
27	Therapy for Non-Clear Cell Histologies in Renal Cancer. <i>Current Clinical Pharmacology</i> , 2011, 6, 169-180.	0.6	8
28	Optimizing the Efficiency and Quality of Sipuleucel-T Delivery in an Academic Institution. <i>Clinical Journal of Oncology Nursing</i> , 2015, 19, 297-303.	0.6	5
29	Body composition, physical function and quality of life in healthy men and across different stages of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 725-732.	3.9	5
30	Feasibility of home-based exercise training in men with metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, , .	3.9	5
31	Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?. <i>Clinical Medicine Insights: Oncology</i> , 2011, 5, CMO.S5977.	1.3	2
32	Homologous Recombination Repair Gene Variants and Outcomes Among Patients With Prostate Cancer Treated With Poly (ADP-ribose) Polymerase Inhibitors. <i>JCO Precision Oncology</i> , 2022, 6, e2100461.	3.0	2
33	Novel Therapies in Castration-Resistant Prostate Cancer. , 2016, , 259-269.		0
34	Prognostic, Predictive, and Surrogate Factors for Individualizing Treatment for Men with Castration-Resistant Prostate Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 292-297.	3.8	0
35	Title is missing!. , 2020, 15, e0228773.		0
36	Title is missing!. , 2020, 15, e0228773.		0

#	ARTICLE	IF	CITATIONS
37	Title is missing!. , 2020, 15, e0228773.		0
38	Title is missing!. , 2020, 15, e0228773.		0